DaVita Inc. (NYSE: DVA) is a major healthcare company that specializes in providing kidney dialysis services. It operates numerous outpatient centers across the United States, offering essential treatments for patients with chronic kidney failure. The company's stock performance is closely tied to the steady demand for these critical medical services.
On May 7, 2026, Andrew Mok of Barclays raised the price target for DaVita to $194.00 from a previous target of $158.00. A price target represents an analyst's estimate of a stock's future value. This new target was announced when the stock was trading at $193.88, indicating the market already shared this positive view.
This optimism is backed by strong first-quarter 2026 results. As highlighted by Zacks, DaVita reported revenues of $3.42 billion, a 5.9% increase from the same period last year. This performance beat revenue estimates for the fourth consecutive quarter, showing consistent growth in the company's sales.
The company's profitability also improved significantly. Adjusted earnings per share (EPS), which measures profit per share of stock, rose by 43.5% to $2.87. DaVita's adjusted operating margin, which shows how much profit it makes from its core business operations, expanded to 19.1% for the quarter.
Following these results, DaVita raised its profit forecast for the full year, as reported by Reuters. The company now expects its 2026 adjusted EPS to be in the range of $14.10 to $15.20. DaVita also continues to buy back its own shares, a move that can increase the value of the remaining shares, offering further investment insights.
